Full Press Release Details
Chief Executive Officer
ELECTROMED, INC. REPORTS FISCAL YEAR 2014 SECOND
New Prague, Minnesota - February 11, 2014 - Electromed, Inc.
(NYSE MKT: ELMD) today announced financial results for the Company's second quarter of fiscal 2014.
Net revenues in the quarter were approximately $3.50 million, a 9% decrease
compared to $3.86 million in the same period of fiscal 2013. The Company reported a net loss of approximately $0.2 million, or
three cents per basic and diluted share, for the second quarter of fiscal 2014, compared to a net loss of approximately $0.4 million,
or five cents per basic and diluted share, for the same period of fiscal 2013.
The modest decline in total revenues in the second quarter of fiscal 2014
was attributable to lower average prices received from health care insurers due to their increased focus on controlling health
care costs as well as more rigorous scrutiny by insurers of reimbursement requests for a wide range of medical devices and other
health care products.
The decline in homecare revenue of approximately $0.4 million in the second
quarter was partially offset by an increase in government/institutional revenue of $0.1 million compared to the same period of
fiscal 2013. Gross margins in the second quarter rose to 72.1% as compared to 65.2% in the same period in the prior year. This
was primarily due to the buildup of inventory in anticipation of the launch of the SmartVest SQL product for which we received
FDA clearance in late December 2013. Overall, the smaller net loss in the second quarter was primarily due to the improved gross
margins and lower operating expenses.
Operating expenses declined about $0.3 million compared with the second
quarter of last year and were essentially flat as a percentage of sales due to the lower revenues in the second quarter of fiscal
2014 as compared to the second quarter of the prior year.
The Company had positive operating cash flow of approximately $0.4 million
and increased its cash balance by approximately $0.2 million during the quarter.
Commenting on the Company's results, Electromed 's Chief Executive
Officer, Kathleen Skarvan said, "We continued to see pressure on our revenues in the second quarter of fiscal 2014 driven
by uncertainty surrounding health care reform and the Affordable Care Act combined with ongoing efforts by health insurers to control
costs. Despite these challenges, we reduced the reported net loss and added cash to the balance sheet and I am proud of the team
for the progress they continue to make in improving the Company's overall financial position.
Results for the Three-Months Ended December 30, 2013
On a very positive note, we announced the launch of the Company's
newest product, the SmartVest SQL, in late December and began shipping it to patients in mid-January. It is a significant step
forward in high frequency chest wall oscillation therapy as it is smaller, lighter and quieter than our previous model, the SV2100.
Patients have been asking for these improvements and we delivered with SQL. We believe it will make therapy adherence even easier,
a goal long sought by physicians and clinicians.
While the environment remains challenging, we believe SQL gives us an advantage
in competing for the attention of doctors, clinicians and patients. We will be rolling SQL out in the domestic HomeCare market
as the third quarter progresses."
About Electromed, Inc.
Electromed, Inc. manufactures, markets, and sells products that provide airway
clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised
pulmonary function. Further information about the Company can be found at www.electromed.com.
Cautionary Statements
Certain statements found in this release may constitute forward-looking
statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect the speaker's
current views with respect to future events and financial performance and include any statement that does not directly relate to
a current or historical fact. Forward-looking statements can generally be identified by the words "believe," "expect,"
"anticipate" or "intend" or similar words. Forward-looking statements made in this release include the
Company's beliefs regarding the impact of industry trends and legislation on revenue, the Company's revenue growth
and cost control strategies, and the Company's beliefs and expectations regarding its SQL product, including the timing of
shipments in the domestic homecare market. Forward-looking statements cannot be guaranteed and actual results may vary materially
due to the uncertainties and risks, known and unknown, associated with such statements. Examples of risks and uncertainties for
Electromed include, but are not limited to, the impact of emerging and existing competitors, the effect of new legislation on our
industry and business, the effectiveness of our sales and marketing and cost control initiatives, changes to reimbursement programs,
and delays in manufacturing and shipment of our products, as well as other factors described from time to time in our reports to
the Securities and Exchange Commission (including our Annual Report on Form 10-K). Investors should not consider any list of such
factors to be an exhaustive statement of all of the risks, uncertainties or potentially inaccurate assumptions investors should
take into account when making investment decisions. Shareholders and other readers should not place undue reliance on "forward-looking
statements," as such statements speak only as of the date of this release.
Financial Tables Follow:
Electromed, Inc. and Subsidiary
Condensed Consolidated Balance Sheets
| December 31, 2013 | June 30, 2013 | |||||||
| Assets | (Unaudited) | |||||||
| Current Assets | ||||||||
| Cash and cash equivalents | $ | 1,236,576 | $ | 503,564 | ||||
| Accounts receivable (net of allowances for doubtful accounts of $45,000) | 7,040,935 | 9,014,043 | ||||||
| Inventories | 2,266,734 | 1,379,594 | ||||||
| Prepaid expenses and other current assets | 298,611 | 428,843 | ||||||
| Income taxes receivable | 868,645 | 538,285 | ||||||
| Deferred income taxes | 557,000 | 557,000 | ||||||
| Total current assets | 12,268,501 | 12,421,329 | ||||||
| Property and equipment, net | 3,761,465 | 3,743,675 | ||||||
| Finite-life intangible assets, net | 1,019,724 | 1,080,734 | ||||||
| Other assets | 348,093 | 310,089 | ||||||
| Total assets | $ | 17,397,783 | $ | 17,555,827 | ||||
| Liabilities and Equity | ||||||||
| Current Liabilities | ||||||||
| Current maturities of long-term debt | $ | 45,156 | $ | 57,540 | ||||
| Accounts payable | 1,301,835 | 643,681 | ||||||
| Accrued compensation | 321,072 | 565,023 | ||||||
| Warranty reserve | 700,000 | 680,000 | ||||||
| Other accrued liabilities | 234,337 | 247,267 | ||||||
| Total current liabilities | 2,602,400 | 2,193,511 | ||||||
| Long-term debt, less current maturities. | 1,274,775 | 1,332,455 | ||||||
| Deferred income taxes | 103,000 | 103,000 | ||||||
| Total liabilities | 3,980,175 | 3,628,966 | ||||||
| Commitments and Contingencies (Note 7) | ||||||||
| Equity | ||||||||
| Common stock, $0.01 par value; authorized: 13,000,000; shares issued and outstanding: 8,114,252 shares | 81,143 | 81,143 | ||||||
| Additional paid-in capital | 13,200,352 | 13,134,938 | ||||||
| Retained earnings | 136,113 | 710,780 | ||||||
| Total equity | 13,417,608 | 13,926,861 | ||||||
| Total liabilities and equity | $ | 17,397,783 | $ | 17,555,827 |
Electromed, Inc. and Subsidiary
Condensed Consolidated Statements of Income
| For the Three Months Ended December 31, | For the Six Months Ended December 31, | |||||||||||||||
| 2013 | 2012 | 2013 | 2012 | |||||||||||||
| Net revenues | $ | 3,501,075 | $ | 3,856,370 | $ | 6,919,253 | $ | 7,887,656 | ||||||||
| Cost of revenues | 978,029 | 1,342,002 | 2,040,375 | 2,552,455 | ||||||||||||
| Gross profit | 2,523,046 | 2,514,368 | 4,878,878 | 5,335,201 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Selling, general and administrative | 2,739,104 | 3,000,532 | 5,463,032 | 5,816,544 | ||||||||||||
| Research and development | 92,735 | 109,250 | 301,843 | 210,440 | ||||||||||||
| Total operating expenses | 2,831,839 | 3,109,782 | 5,764,875 | 6,026,984 | ||||||||||||
| Operating loss | (308,793 | ) | (595,414 | ) | (885,997 | ) | (691,783 | ) | ||||||||
| Interest expense, net of interest income of $3,940, $10,975, $11,338, and $15,322 respectively | 19,469 | 25,777 | 34,670 | 62,516 | ||||||||||||
| Net loss before income taxes | (328,262 | ) | (621,191 | ) | (920,667 | ) | (754,299 | ) | ||||||||
| Income tax benefit (expense) | 89,000 | 210,000 | 346,000 | 272,000 | ||||||||||||
| Net loss | $ | (239,262 | ) | $ | (411,191 | ) | $ | (574,667 | ) | $ | (482,299 | ) | ||||
| Loss per share: | ||||||||||||||||
| Basic and diluted | $ | (0.03 | ) | $ | (0.05 | ) | $ | (0.07 | ) | $ | (0.06 | ) | ||||
| Weighted-average common shares outstanding: | ||||||||||||||||
| Basic | 8,114,252 | 8,114,252 | 8,114,252 | 8,114,252 | ||||||||||||
| Diluted | 8,114,252 | 8,114,252 | 8,114,252 | 8,114,252 |
Electromed, Inc. and Subsidiary
Condensed Consolidated Statements of Cash Flows
| For the Six Months Ended December 31, | ||||||||
| 2013 | 2012 | |||||||
| Cash Flows From Operating Activities | ||||||||
| Net loss | $ | (574,667 | ) | $ | (482,299 | ) | ||
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||||||||
| Depreciation | 259,074 | 231,918 | ||||||
| Amortization of finite-life intangible assets | 63,235 | 66,234 | ||||||
| Amortization of debt issuance costs | 8,136 | 6,377 | ||||||
| Share-based compensation expense | 65,414 | 86,382 | ||||||
| Loss on disposal of property and equipment | 28,178 | 22,020 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 1,973,108 | 1,125,717 | ||||||
| Inventories | (887,140 | ) | 493,388 | |||||
| Prepaid expenses and other assets | (210,972 | ) | (272,371 | ) | ||||
| Accounts payable and accrued liabilities | 407,275 | (74,972 | ) | |||||
| Net cash provided by operating activities | 1,131,641 | 1,202,394 | ||||||
| Cash Flows From Investing Activities | ||||||||
| Expenditures for property and equipment | (291,044 | ) | (482,122 | ) | ||||
| Expenditures for finite-life intangible assets | (2,225 | ) | (28,092 | ) | ||||
| Net cash used in investing activities | (293,269 | ) | (510,214 | ) | ||||
| Cash Flows From Financing Activities | ||||||||
| Net payments on revolving line of credit | - | (1,168,128 | ) | |||||
| Principal payments on long-term debt including capital lease obligations | (70,064 | ) | (220,871 | ) | ||||
| Payments of deferred financing fees | (35,296 | ) | - | |||||
| Net cash used in financing activities | (105,360 | ) | (1,388,999 | ) | ||||
| Net increase (decrease) in cash and cash equivalents | 733,012 | (696,819 | ) | |||||
| Cash and cash equivalents | ||||||||
| Beginning of period | 503,564 | 1,702,435 | ||||||
| End of period | $ | 1,236,576 | $ | 1,005,616 |